12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oncotype DX colon cancer assay: Postmarketing study data

An analysis of 141 patients with stage II colon cancer showed that physicians reduced the number of recommendations for adjuvant chemotherapy by 22% after receiving results on the risk of recurrence as determined by the Oncotype DX colon cancer assay. Genomic Health said the reduction led to overall direct medical care cost savings of an average of...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >